Tulisokibart for adults with active pulmonary sarcoidosis, compared with placebo
Tests tulisokibart against placebo in adults with active pulmonary sarcoidosis.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Shreveport, United StatesSee the site
- Trial code
- NCT07867938
- EU 2025-524270-42-00
- U1111-1330-0840
- Registry title
- A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 158 people, planned
- Started
- 3 Nov 2026
- Expected to end
- 11 Jan 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tulisokibart
- Placebo
- Background prednisone therapy
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active sarcoidosis of the lungs (pulmonary sarcoidosis). It tests tulisokibart against placebo, both given with prednisone.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Sarcoidosis diagnosed at least 6 months before screening and confirmed by tissue biopsy. Lung tissue involvement seen on chest X-ray or chest HRCT scan. Active pulmonary sarcoidosis within 3 months before screening.
- Earlier treatment
- People getting treatment for pulmonary hypertension (high blood pressure in the lungs) cannot join.
Main reasons for not taking part
- Cancer in the past, with less than 5 years free of disease
- Sarcoidosis of the heart, eyes, nerves or elsewhere that needs whole-body treatment, or a serious heart tracing (ECG) problem
- Active tuberculosis now or in the past, or a fungal lung infection within 12 months without finished treatment
- Löfgren syndrome
- Smoking or vaping nicotine, tobacco or cannabis within 6 months before screening
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Has a diagnosis of sarcoidosis of ≥6 months before Screening confirmed by tissue biopsy
- Has lung parenchymal involvement consistent with pulmonary sarcoidosis (PS) by chest X-ray or chest high-resolution computed tomography (HRCT) either via historical evidence or at Screening
- Has active PS within 3 months before Screening
Who cannot take part
- Is receiving treatment for pulmonary hypertension
- Has a history of fungal respiratory infection within 12 months before screening without documentation of completed treatment
- Is a current smoker defined as smoking or vaping of inhaled preparations of nicotine, tobacco, or cannabis preparations within 6 months before Screening
- Has cardiac, ocular, neurosarcoidosis, or other manifestations of sarcoidosis that requires systemic treatment that may interfere with protocol specifications, or has a clinically significant electrocardiogram abnormality that requires evaluation or intervention
- Has a diagnosis of or currently has a clinical presentation consistent with Löfgren syndrome
- Has active tuberculosis (TB) or history of active TB
- Has any condition that may interfere with the ability to adhere to oral corticosteroid therapy or taper
- Has a history of cancer and is disease free for <5 years
- The main exclusion criteria include but are not limited to the following:
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Care Access Research Llc (Site 2725)Shreveport, United StatesContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).
Read full original descriptionShow less
This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.
The 2 groups in the trial
- TulisokibartTreatment being tested
Participants receive background therapy of prednisone plus tulisokibart.
Treatment: Tulisokibart and Background prednisone therapy
- PlaceboPlacebo, for comparison
Participants receive background therapy of prednisone plus placebo.
Treatment: Placebo and Background prednisone therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Active Pulmonary Sarcoidosis
- Plain-language title
- Tulisokibart for adults with active pulmonary sarcoidosis, compared with placeboGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07867938, who can take part
- Record updated
- 9 November 2026